AIM - AIM ImmunoTech to further study long COVID therapy after early positive data

• Immuno-pharma company AIM ImmunoTech ( NYSE: AIM ) announced plans to seek FDA clearance to study its experimental long COVID therapy Ampligen on Thursdasy after the company reported preliminary pilot study data for the candidate.
• AIM ImmunoTech ( AIM ) generated data from an ongoing Phase 3 study for Ampligen targeted at patients with myalgic encephalomyelitis/chronic fatigue syndrome.
• The open-label trial included four post-COVID subjects whose fatigue-related measures indicated a clinically significant decrease by week 12 from the baseline following the treatment, according to investigators.
• Partly due to these preliminary data, AIM ImmunoTech ( AIM ) expects to submit an IND application with the FDA to initiate a Phase 2 study for a 12-week treatment of Ampligen targeting long COVID.
• According to a recent study conducted by the Centers for Disease Control and Prevention (CDC), One in five COVID-19 survivors aged 18 – 64 years in the U.S. suffer from at least one condition linked to long COVID.

For further details see: